Vericel Corporation (VCEL)

CIK 0000887359 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-07-30) · 99.1
Q1-2026 8-K (2026-05-07) · 99.1
Latest FY-2025 8-K (2026-02-26) · 99.1  |  8-K (2026-01-13) · 99.1
Q3-2025 8-K (2025-11-06) · 99.1
Q2-2025 8-K (2025-07-31) · 99.1
Q1-2025 8-K (2025-05-08) · 99.1
FY-2024 8-K (2025-02-27) · 99.1  |  8-K (2025-01-14) · 99.1 · 99.2
Q3-2024 8-K (2024-11-07) · 99.1
Q2-2024 8-K (2024-08-01) · 99.1
Q1-2024 8-K (2024-05-08) · 99.1
FY-2023 8-K (2024-02-29) · 99.1  |  8-K (2024-01-09) · 99.1 · 99.2
Q3-2023 8-K (2023-11-08) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Audit Information
—
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Comprehensive Income (loss)
Consolidated Statements of Shareholders' Equity
Consolidated Statements of Cash Flows
Notes
Basis of Presentation
—
Commitments and Contingencies
Cybersecurity Risk Management and Strategy Disclosure
—
Employee Benefit Plans
—
Employee Savings Plan
—
Fair Value Measurements
Income Taxes
—
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Investments
Leases
Net Income (loss) Per Common Share
Net Loss Per Common Share
Nexobrid License and Supply Agreements
Organization
Pay Vs Performance Disclosure
Revenue
Revolving Credit Agreement
Segment Information
Selected Balance Sheet Components
Shareholder's Equity
—
Stock-based Compensation
Subsequent Events
—
Summary of Significant Accounting Policies
—
The Barda Agreement
—